Suppr超能文献

胆囊癌的术后放化疗。

Postoperative chemoradiotherapy for gallbladder cancer.

机构信息

Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, 110-744, Seoul, Korea.

出版信息

Strahlenther Onkol. 2012 May;188(5):388-92. doi: 10.1007/s00066-012-0074-7. Epub 2012 Mar 10.

Abstract

PURPOSE

The goal of this work was to analyze the outcome of adjuvant chemoradiotherapy for patients with gallbladder cancer who underwent surgical resection and to identify the prognostic factors for these patients.

PATIENTS AND METHODS

Between August 1989 and November 2006, 47 patients with gallbladder cancer underwent surgical resection followed by adjuvant radiotherapy. There were 21 males and 26 females, and median age was 60 years (range 44-75 years). Postoperative radiotherapy was delivered to the tumor bed and regional lymph nodes up to 40-50 Gy at 2 Gy/fraction; 41 patients also received intravenous 5-fluorouracil as a radiosensitizer. Median follow-up duration was 48 months for survivors.

RESULTS

There were 2 isolated locoregional recurrences, 14 isolated distant metastases, and 7 combined locoregional and distant relapses. The 5-year overall survival rate was 43.7%. According to the extent of resection, the 5-year overall survival rates were 52.8%, 20.0%, and 0% in R0-, R1-, and R2-resected patients, respectively (p = 0.0038). On multivariate analysis incorporating extent of resection, T stage, N stage, performance of lymph node dissection, and histologic differentiation, extent of resection was the only prognostic factor associated with overall survival (p = 0.0075). Among the 37 patients with R0 resection, there was no difference of 5-year overall survival rates in patients with N0, N1, and Nx diseases (46.2%, 60.0%, and 44.4%, respectively, p = 0.6246). As for significant treatment-related morbidity, there was only 1 patient with grade 4 gastric ulcer.

CONCLUSION

Adjuvant chemoradiotherapy after R0 resection can achieve a good long-term survival rate in gallbladder cancer patients, even in those with lymph node metastases, and may play a role for patients who underwent R0 resection of primary tumor without lymph node dissection.

摘要

目的

本研究旨在分析接受手术切除并接受辅助放化疗的胆囊癌患者的预后,并确定这些患者的预后因素。

方法

1989 年 8 月至 2006 年 11 月,47 例胆囊癌患者接受了手术切除加辅助放疗。其中男性 21 例,女性 26 例,中位年龄 60 岁(范围 44-75 岁)。术后放疗采用 2Gy/次分割,总剂量 40-50Gy,照射肿瘤床和区域淋巴结;41 例患者还接受静脉氟尿嘧啶作为增敏剂。生存者的中位随访时间为 48 个月。

结果

孤立局部复发 2 例,孤立远处转移 14 例,局部和远处联合复发 7 例。5 年总生存率为 43.7%。根据切除范围,RO、R1 和 R2 切除患者的 5 年总生存率分别为 52.8%、20.0%和 0%(p=0.0038)。多因素分析纳入了切除范围、T 分期、N 分期、淋巴结清扫情况和组织学分化程度,结果显示切除范围是唯一与总生存相关的预后因素(p=0.0075)。在 37 例 RO 切除患者中,N0、N1 和 Nx 疾病患者的 5 年总生存率无差异(分别为 46.2%、60.0%和 44.4%,p=0.6246)。在显著的治疗相关发病率方面,仅有 1 例患者出现 4 级胃溃疡。

结论

RO 切除术后辅助放化疗可使胆囊癌患者获得良好的长期生存率,即使存在淋巴结转移,也可能对未行淋巴结清扫的 RO 切除原发性肿瘤患者发挥作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验